Mediators of Inflammation / 2012 / Article / Tab 1

Clinical Study

Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy

Table 1

Changes in DAS28, CRP, and ultrasonography data in 34 patients undergoing anti-TNF-alpha-adalimumab therapy due to RA refractory to conventional DMARDs.

Day 0Day 14Month 12Day 0 verus Day 14Day 0 versus Month 12
VariableMean±SDMedian(IQR)Mean±SDMedian(IQR)Mean±SDMedian(IQR)

FMD%4.5±4.03.6(2.1–7.0)6.1±3.95.7(2.9–8.7)7.4±2.86.9(5.4–9.2)0.03<0.001
NTG%19.3±7.519.5(14.8–24.2)20.1±8.919.6(15.0–27.5)22.3±7.819.7(16.5–24.6)0.520.08
Carotid IMT (mm)0.65±0.160.64(0.52–0.75)0.69±0.210.68(0.53–0.79)0.30
DAS285.9±0.75.9(5.4–6.4)4.5±1.14.6(4.0–5.3)3.3±1.53.3(2.1–4.2)<0.001<0.001
CRP (mg/L)15.6±16.69.1(3.5–21.0)8.9±14.04.9(1.2–8.5)6.8±11.83.0(1.1–8.4)0.0080.07

(FMD: flow-mediated endothelium dependent vasodilatation; NTG: flow-mediated endothelium independent vasodilatation; IMT: intima-media thickness; CRP: C-reactive protein).